Related Experiment Video
Updated: Oct 27, 2025
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management
Alexandra C Hristov1, Trilokraj Tejasvi2, Ryan A Wilcox3
1Departments of Pathology and Dermatology, North Campus Research Complex, Ann Arbor, Michigan, USA.
Disease Overview:
Cutaneous T-cell lymphomas are a heterogenous group of T-cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS).
Diagnosis:
The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Risk-Adapted Therapy:
TNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis for a "risk-adapted," multi-disciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin-directed therapies is preferred, as both disease-specific and overall survival for these patients is favorable. In contrast, patients with advanced-stage disease with significant nodal, visceral or blood involvement are generally approached with systemic therapies, including biologic-response modifiers, histone deacetylase inhibitors, or antibody-based strategies, in an escalating fashion. In highly-selected patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some patients.
